Skip to main content

Table 2 Characteristics at initiation of antiretroviral treatment (ART) and during follow-up (last visit) of HIV-infected adults in the three participating centers, IeDEA West Africa, December 2009 to December 2011

From: Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the IeDEA West Africa collaboration

Characteristics Total Aconda-CePReF CMSDS CTA/CNHU
N = 978 n = 570 n = 198 n = 210
At ART initiation         
Sex, woman, n (%) 692 (71) 420 (74) 140 (71) 119 (57)
Age (years), median (IQR) 39 (33–45) 36 (31–44) 35 (31–41) 36 (31–42)
BMI (Kg/m2), median (IQR) 20.1 (17.9-22.7) 19.7 (17.6-22.2) 20.8 (18.7-23.7) 21.0 (18.8-24.6)
CD4 (/mm3), number, median (IQR) 137 (59–239) 136 (61–249) 157 (60–242) 108 (47–180)
Antiretroviral treatment, n (%)         
   2NRTIs + 1NNRTIs 678 (69.3) 381 (66.8) 135 (68,2) 162 (77,1)
   2NRTIs + 1PI 87 (9) 48 (8) 26 (13) 13 (6)
   Other 213 (22) 141 (25) 37 (19) 35 (17)
Follow-up data*         
Total follow-up (months), median (IQR) 34.9 (16.3-67.1) 35.5 (14.6-66.2) 35.0 (18.2-54.1) 33.5 (16.9-76.6)
Follow-up until event (months), median (IQR) ((I(((IQR) 23.1 (3.4-54.6) 24.6 (2.6-55.5) 18.7 (3.5-43.1) 23.2 (5.8-66.2)
CD4 cell/mm3 median (IQR) 269 (103–467) 267 (102–453) 289 (124–517) 237 (73–468)
WHO stage, n (%)         
   Stage 1 or 2 167 (17.1) 29 (5) 119 (60.2) 19 (9)
   Stage 3 242 (24.7) 128 (22) 48 (24.2) 66 (31)
   Stage 4 80 (8.2) 41 (7) 27 (13.6) 12 (6)
  1. IQR = Interquartile Range.
  2. BMI = Body Mass Index.
  3. WHO = World Health Organisation.
  4. ART = Antiretroviral Treatment.
  5. Aconda-CePReF = Centre for Care, Research and Training.
  6. CMSDS = Medical Centre for Monitoring Blood Donors.
  7. CTA/CNHU = Outpatient Treatment Centre of the National University Hospital.
  8. NNRTIs = Non Nucleoside Reverse Transcriptase Inhibitors.
  9. PIs = Protease Inhibitors.
  10. AZT = Zidovudine.
  11. D4T = Stavudine.
  12. 3TC = Lamivudine.
  13. *: close to the event: At the time of the morbid event.